Collecting tumor tissue from lung cancer patients during immunotherapy progression
Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
This study is collecting tumor samples from lung cancer patients who are not responding to immunotherapy to learn more about how their cancer is changing.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Boulogne-Billancourt) |
| Trial ID | NCT04300062 on ClinicalTrials.gov |
What this trial studies
This study aims to collect tumor tissue samples from patients with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) who have experienced disease progression while undergoing treatment with immune checkpoint inhibitors (ICI). The samples will be stored in a biological resources center at Ambroise Paré hospital for future analysis of the molecular mechanisms involved in cancer progression under ICI treatment. The research will be conducted by the EA 4340 unit, focusing on biomarkers and clinical trials in cancerology and onco-hematology at the University of Paris-Saclay.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with NSCLC or SCLC who have progressed on ICI therapy.
Not a fit: Patients who are unable to provide informed consent or have technical difficulties in undergoing a rebiopsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of lung cancer progression under immunotherapy, potentially leading to improved treatment strategies.
How similar studies have performed: While the specific approach of rebiopsy during immunotherapy progression is relatively novel, similar studies have shown promise in understanding cancer biology and treatment responses.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed NSCLC or SCLC; * Patient treated priorly by ICI and progressed under ICI; * Have provided written informed consent for the study; * Be \>/= 18 years of age on day of signing informed consent. Exclusion Criteria: * Patient under guardianship or curatorship; * Unable to provide written informed consent for the study; * Technical impossibility to carry out tissular rebiopsy under local anesthesia.
Where this trial is running
Boulogne-Billancourt
- Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP — Boulogne-Billancourt, France (Recruiting)
Study contacts
- Principal investigator: Etienne Giroux Leprieur, MD, PhD — Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
- Study coordinator: Etienne Giroux Leprieur, MD, PhD
- Email: etienne.giroux-leprieur@aphp.fr
- Phone: +33 1 49 09 58 02
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.